Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric Anesthesia Risks Require Collaborative Studies, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

No organization acting by itself can hope to study the neurological risks of anesthesia in infants and young children, the agency says.

You may also be interested in...



FDA’s Sedation Product Workshop Will Be A Solo Affair

The agency had previously solicited proposals that an outside body or bodies evaluate the issues and sponsor a conference, but has now decided to do the work for the May 3 event in-house, albeit with outside input.

Pediatric Researcher Expresses Frustration With FDA Delay On Ketamine Trial

K.J.S. "Sunny" Anand, director of critical care at Le Bonheur Children's Hospital, said he has been waiting two and a half years for the agency to clear an IND for the drug.

Pediatric Researcher Expresses Frustration With FDA Delay On Ketamine Trial

K.J.S. "Sunny" Anand, director of critical care at Le Bonheur Children's Hospital, said he has been waiting two and a half years for the agency to clear an IND for the drug.

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel